Texas Public Radio: Clinical trial for first Alzheimer’s drug with effect on cognitive decline looks for South Texas recruits

Posted on: Friday, December 9th, 2022

Arash Salardini, MD

Arash Salardini, MD, neurologist at the Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was interviewed for this story on Texas Public Radio (KSTX) on a clinical trial in South Texas for a drug to treat cognitive decline.

The clinical trial, AHEAD 3-45, is to assess whether IV infusions of the antibody (lecanemab) can delay cognitive decline if administered early, before symptoms begin. Lecanemab reduces levels of amyloid, a protein linked to Alzheimer’s disease.

Lecanemab has aroused some excitement recently and has been covered extensively by the media. A separate Phase III clinical trial, published Nov. 29 in The New England Journal of Medicine, showed that lecanemab slowed cognitive decline and cleared amyloid from the brain in participants with cognitive symptoms due to Alzheimer’s disease.


To read the article, visit TPR.org.

Article Categories: In the News, Research and Progress